ArticleMolecular biology reports2025
Genetic associations of miR-145 (rs353291) and miR-143/145 (rs3733846) with preeclampsia risk: a case-control analysis in maternal and cord blood.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreeclampsia (PE), affecting 1-5% of pregnancies, is a major cause of maternal and neonatal morbidity. Dysregulated microRNAs, especially miR-145 and the miR-143/145 cluster, contribute to PE via placental and vascular dysfunction. This study examined the rs353291 and rs3733846 polymorphisms in maternal and cord blood to assess PE susceptibility in Iranians.
methodsA case-control study was conducted with 320 maternal samples (160 PE, 160 controls) and 202 cord samples (101 PE, 101 controls). PE was diagnosed according to the ACOG of Obstetrics and Gynecology criteria (≥ 140/90 mmHg after 20 weeks of proteinuria). Genomic DNA from maternal and cord blood was genotyped for rs353291 and rs3733846 using tetra-primer ARMS-PCR and confirmed by Sanger sequencing. Associations tested in SNPStats under codominant, dominant, recessive, overdominant, and log-additive models.
resultsIn cord blood, the rs353291 G allele frequency was higher in PE (43% vs. 32%, p < 0.05), with the homozygous G/G genotype conferring a threefold increased risk (OR = 3.31, p = 0.032). Conversely, rs3733846 A/G heterozygosity reduced the PE risk (OR = 0.24, p = 0.0002). In the maternal blood, rs353291 A allele carriers showed an elevated risk (OR = 1.66, p = 0.025), while rs3733846 exhibited no association.
conclusionMaternal and fetal miR-145 and miR-143-145 polymorphisms had distinct effects on PE. Cord rs353291 G is linked to placental and fetal vascular dysfunction, maternal rs353291 A is linked to systemic inflammation, and cord rs3733846 A/G appears to be protective. These findings suggest the potential of these variants as biomarkers for PE risk; however, further validation in larger, multi-ethnic cohorts is required before clinical application.
Indexed as
Identifiers
41369960What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.